Dr. Moss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
345 Saxony Rd
Ste 105
Encinitas, CA 92024Phone+1 760-436-6404Fax+1 760-462-3986
Summary
- Allergy/immunology
Education & Training
- National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1990 - 1993
- Stony Brook Medicine/University HospitalResidency, Pediatrics, 1987 - 1990
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1987
Certifications & Licensure
- CA State Medical License 1994 - 2026
- PA State Medical License 2003 - 2004
- MD State Medical License 1990 - 1993
- American Board of Allergy and Immunology Allergy & Immunology
- National Board of Physicians and Surgeons Allergy and Immunology
Clinical Trials
- A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis Start of enrollment: 2010 Jul 01
Publications & Presentations
PubMed
- 5 citationsBrief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients.Kavita Mathi, Yael Rosenberg-Hasson, Holden T. Maecker, Dennis J. Carlo, Ronald B. Moss
Clinical Immunology. 2021-08-21 - 26 citationsHigher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.Ronald B. Moss, Meghan McCabe Pryor, Rebecca Baillie, Katherine Kudrycki, Christina M. Friedrich
Plos One. 2020-06-16 - An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg...Ronald B. Moss, Fiona Carleton, Charles P. Lollo, Dennis J. Carlo
Journal of Opioid Management. 2020-05-01
Press Mentions
- Symjepi vs EpiPen: Incorrect Usage Rates Among Untrained TeensMarch 9th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: